BioInsights - The drive for standardization in cellular starting material collection for cell therapy
Raw & starting materials quality ,sourcing and management

The drive for standardization in cellular starting material collection for cell therapy

Cell & Gene Therapy Insights 2022; 8(10), 1393–1397

DOI: 10.18609/cgti.2022.204

Published: 22 November 2022
Interview
Anh Nguyen Jones

David McCall, Commissioning Editor, BioInsightsspeaks to Anh Nguyen Jones, Senior Director, Cell Therapy Patient Operations, GentiBio

Anh Nguyen Jones has over 13 years of Cell and Gene Therapy experience advancing multiple cell therapy programs through clinical and commercial development working closely with Clinical, Commercial, Quality and Technical Operations. Anh joined GentiBio in 2022 as the Senior Director of Patient Operations, leading the teams responsible for the management of cell collection centers, patient scheduling, cell logistics and chain of identity. Prior to joining GentiBio, Anh was Director of Global Apheresis Operations at Bristol Myers Squibb (previously Celgene, Juno Therapeutics) where she led a global team that built and maintained the global network for cell collection centers in support of all cell therapy clinical trials and the commercialization of Breyanzi and Abecma across the globe. Prior to BMS, Anh was in varying roles within Quality Assurance and Apheresis Operations at Dendreon, commercializing the first FDA approved cancer vaccine, Provenge. She holds a BSc in Biochemistry at the University of Washington.